Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01330979 · ClinicalTrials.gov registry record · Phase 2
24-hour Efficacy of AR-12286
A Phase 2 study, sponsored by Aerie Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT01330979 is a Phase 2 study that has completed, run by Aerie Pharmaceuticals. The registered enrollment target is 5 participants.
The verdict
NCT01330979, a Phase 2 study, has completed, sponsored by Aerie Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
An open-label, non-comparative, pilot evaluation of the 24-hour ocular hypotensive efficacy of AR-12286 in patients with open-angle glaucoma or ocular hypertension
Interventions
- DRUG AR-12286 0.5% Ophthalmic Solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2011-05 |
| Est. Completion | 2012-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01330979
The ClinicalTrials.gov registry entry for NCT01330979 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aerie Pharmaceuticals, which has 32 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AR-12286 0.5% Ophthalmic Solution is the first listed.
NCT01330979 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01330979 about?
NCT01330979 is a clinical study titled "24-hour Efficacy of AR-12286". An open-label, non-comparative, pilot evaluation of the 24-hour ocular hypotensive efficacy of AR-12286 in patients with open-angle glaucoma or ocular hypertension
What is the current status of trial NCT01330979?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2011-05. Estimated completion is 2012-08.
What interventions are being tested in trial NCT01330979?
The interventions under investigation include: AR-12286 0.5% Ophthalmic Solution (DRUG).
Who is sponsoring clinical trial NCT01330979?
This trial is sponsored by Aerie Pharmaceuticals, which has 32 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.